Analytical Reports on Teva Pharmaceutical Industries Limited and Forest Laboratories Inc. - Regulatory Changes Pending for Generics
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 09/07/11 -- provides members with proprietary analysis of over 10,000 stocks which is updated every day. Today, members can receive their complimentary stock analysis on (NASDAQ: TEVA) and (NYSE: FRX). Sign up now on to get your free reports on these stocks.
The proposed Generic Drug User Fee Act (GDUFA) still needs Congressional approval, but both the generic drug industry and the Food and Drug Administration appear close to a deal.
brings investors free classic analysis on Teva Pharmaceutical Industries Limited, Forest Laboratories Inc. and other companies within the Drug Manufacturers - Other industry. This type of analysis is only a fragment of the information members have available to them. To learn more we encourage investors to sign up at .
Typically, only branded-drug makers had to pay to accelerate approval processes at the FDA. Passage of the GDUFA will change that and require generic drug manufacturers to pay as well. Since getting generics to market is already time sensitive, drug makers will likely have little choice but to pay for quicker timetables.
Initially, it seems that fees will have a negative impact and only eat at margins. While this is true, generics should be able to pass along some of the costs to consumers because all drug makers in the market will be subject to the same fees. The fees may actually have a positive influence on competition. Smaller companies may now be hesitant to compete over a drug with multiple companies already producing a generic version of it.
Moving forward, investors in established, leading generic drug manufacturers like Teva Pharmaceutical Industries Ltd. and Forest Laboratories Inc. will want to track the status of the GDUFA. gives traders a unique insight about and by registering now at
or
.
Signal Watch's #1 goal is to help customers successfully engage the markets. For over 20 years, we have been developing the most powerful trading software available anywhere. But the software is only part of our mission. We also provide education and customer support designed to enable our customers to take control of their financial future.
Read our disclaimer by clicking on the following link
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 07.09.2011 - 12:25 Uhr
Sprache: Deutsch
News-ID 62820
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Commercial & Investment Banking
Diese Pressemitteilung wurde bisher 164 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Analytical Reports on Teva Pharmaceutical Industries Limited and Forest Laboratories Inc. - Regulatory Changes Pending for Generics"
steht unter der journalistisch-redaktionellen Verantwortung von
Signal Watch (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
